DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,498,539
|Title:||Affinity-based controlled release system|
|Abstract:||Prolonged or extended release of bioactive protein is achieved using an affinity-based approach which exploits the specific binding of Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methylcellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. Controlled release of chondroitinase ABC (ChABC) is also described.|
|Inventor(s):||Shoichet; Molly Sandra (Toronto, CA), Vulic; Katarina (Oakville, CA)|
|Patent Claims:||1. An extended release composition comprising: (a) a chimeric molecule comprising a biologically active molecule, and a first binding moiety covalently linked thereto; and (b) a polymer comprising a polymeric matrix having a second binding moiety, which specifically binds with the first binding moiety, covalently linked to the matrix, wherein the first and second binding moieties are reversibly bound to each other in a
complex having a dissociation constant Kd of between 10.sup.-3 and 10.sup.-9 M.
2. The composition of claim 1, wherein the polymeric matrix comprises monomeric units, wherein, on average, each unit from which the matrix is produced includes between 0.25 and 3 functional groups capable of forming a covalent linkage with the second binding moiety from which the polymer is produced, and, on average, the fraction of said monomeric units of the polymeric matrix which form said covalent linkage with at least one said second binding moiety is between 1/50 and 1/1, inclusively.
3. The composition of claim 2, wherein, on average, the polymer includes 1 second binding moiety covalently linked to at least 1 of 100 monomeric units and up to 1 of 1 monomeric units.
4. The composition of claim 3, wherein each said monomeric unit covalently linked to a second binding moiety has from 1 to 3 said second binding moieties covalently linked thereto.
5. The composition of claim 3, wherein the polymeric matrix comprises a cellulose derivative.
6. The composition of claim 3, wherein the polymeric matrix comprises a hydroxyl-substituted polysaccharide having a degree of substitution (DS) of between 0.5.ltoreq.DS.ltoreq.(N-0.2), wherein N is the total theoretical degree of substitution for a monomeric unit of the polymeric matrix, wherein said substituent is an alkyl group.
7. The composition of claim 1, wherein the polymer is selected from the group consisting of polyacrylates; ethylene-vinyl acetates; acyl substituted cellulose acetates; non-degradable polyurethanes; polystyrenes; polyvinyl chlorides; polyvinyl fluorides; poly(vinyl imidazoles); chlorosulphonate polyolefins; polyethylene oxides; poly(propylene oxides); poly(ethylene), poly(propylene); cellulose or derivatives thereof; polyesters, poly(alpha hydroxyl esters), poly(lactide), poly(glycolide), copolymers of lactide and glycolide, polyhydroxybutyrate, polycaprolactone, copolymers of lactic acid and lactone, copolymers of lactic acid and poly(ethylene glycol), copolymers of .alpha.-hydroxy acids and .alpha.-amino acids (polydepsipeptides), poly(peptides), polyanhydrides, polyorthoesters, polyphosphazenes, copolymers of hydroxybutyrate and hydroxyvalerate, poly(ethylene carbonate), polyethyleneterephthalate or mixtures of these polymers, lactide homopolymers poly(L lactide), poly(D,L-lactide), copolymers of lactide and glycolide, 50:50 poly(DL lactide co glycolide) (PLG), polycarbonates, degradable polyurethanes, poly(ortho esters), poly(dioxanone), hyaluronan or derivatives thereof, methyl cellulose or derivatives thereof, alginate, chitosan, agarose, oligomers of poly(lactic acid), lactides, copolymers of PEG and amino acids, conjugates of PEG with polysaccharides, and a conjugate produced from dextran and polyoxyethylene glycol monomethyl ether.
8. The composition of claim 1, wherein the biologically active molecule is selected from the group consisting of acetaminophen, baclofen, ibuprofen, fluriprofen, ketoprofen, voltaren, phenacetin, salicylamide, naproxen, indomethacin, chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, phenyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, brompheniramine maleate, dexbrompheniramine maleate, clemastine fumarate, triprolidine, dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine, amebicides, broad and medium spectrum fungal medications, monobactams and viral agents, theophylline, albuterol, terbutaline, diltiazem, propranolol, nifedepine, clonidine, alpha adrenoceptor agonists, alpha receptor blocking agents, alpha and beta receptor blocking agents, angiotensin converting enzyme inhibitors, beta blocking agents, calcium channel blockers, cardiac glycosides, thioridazine, diazepam, meclizine, ergoloid mesylates, chlorpromazine, carbidopa, levodopa, potassium chloride, lithium carbonate, iron, chromium, molybdenum, potassium, minocycline, cyclosporine A, synthetic thyroid hormone, thyroxine sodium, human chorionic gonadotrophin (HCG), corticotrophin, human growth hormone (HGH), erythropoietin (EPO), ACTH, anabolics, androgen and estrogen combinations, androgens, corticoids and analgesics, estrogens, glucocorticoid, gonadotropin, gonadotropin releasing, hypocalcemic, menotropins, parathyroid, progesterone, progestogen, progestogen and estrogen combinations, somatostatin-like compounds, urofollitropin, vasopressin, methyl prednisolone, GM1 ganglioside, cAMP, water-soluble vitamins, veterinary formulations, EGF, FGF2, chondroitinase ABC (ChABC), neurotrophins, peptides, peptide mimetics DNA, and, small interfering RNAs.
9. A composition according to claim 1, wherein the polymer matrix is a reverse thermal gelling polymer hydrogel.
10. A composition according to claim 1, wherein the polymer matrix comprises methylcellulose.
11. A composition according to claim 10, further comprising hyaluronan.
12. A composition according to claim 11, further comprising unmodified methylcellulose.
13. A composition according to claim 12, wherein the first binding moiety of the chimeric molecule comprises an SH3 binding domain, and the second binding moiety comprises a peptidyl ligand.
14. A composition according to claim 13, wherein said peptidyl ligand is selected from the group consisting of KPPVVKKPHYLS (SEQ ID NO:6) and KKTKPTPPPKPSHLKPK (SEQ ID NO:7), and a combination thereof.
15. A composition according to claim 14, wherein the biologically active molecule comprises fibroblast growth factor (FGF2).
16. A composition according to claim 14, wherein the biologically active molecule comprises chondroitinase ABC (ChABC).
17. A composition according to claim 5, wherein the polymer matrix is a reverse thermal gelling polymer hydrogel.
18. An extended release composition comprising: (a) a chimeric molecule comprising a biologically active molecule, and a first binding moiety covalently linked thereto; and (b) a polymer comprising a polymeric matrix having a second binding moiety, which specifically binds with the first binding moiety, covalently linked to the matrix, wherein the first and second binding moieties are reversibly bound to each other and the ratio of the second binding moiety to the first binding moiety in the composition is at least 10:1.
19. An injectable pharmaceutical composition comprising: (a) a chimeric protein comprising a biologically active peptide and a protein binding domain fused thereto; and (b) a biocompatible injectable hydrogel polymer comprising a polymeric matrix having a peptidyl ligand covalently linked thereto, wherein the peptidyl ligand is reversibly bound to the protein binding domain of the chimeric protein to form a complex having a dissociation constant Kd of between 10.sup.-3 and 10.sup.-9 M and provide extended delivery of the protein to a subject for at least one week.
20. A composition according to claim 19, wherein the protein binding domain is an SH3 domain.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Ferring||BRAVELLE||urofollitropin||INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS||021289||001||2002-05-06||Start Trial||2040-03-30||DISCN||search|
|Ferring||BRAVELLE||urofollitropin||INJECTABLE; SUBCUTANEOUS||021484||001||2002-12-19||Start Trial||2040-03-30||RX||search|
|Ferring||MENOPUR||menotropins (fsh;lh)||INJECTABLE;SUBCUTANEOUS||021663||001||2006-03-20||Start Trial||2040-03-30||RX||search|
|Ferring Pharmaceuticals Inc.||MENOPUR||menotropins||KIT||021663||1||2004-10-29||Start Trial||2040-03-30||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.